Multiple reports have indicated that the antiretroviral drug tenofovir has renal toxicity. The NEAT 001 trial provided the opportunity of comparing the nephrotoxocity risk of tenofovir containing regimen with a tenofovir-sparing regimen.
The objective of this ancillary study was to compare changes in renal function and proximal renal tubular function between the two treatments strategies in NEAT 001.
Assessments were part of the main study and all patients included in the main study participated in this ancillary study.